Factorial and Honeycomb Join Forces for Breakthrough in Single-Cell DNA Sequencing
Factorial Biotechnologies, recognized for its advancements in single-cell sequencing, has recently announced a strategic partnership with Honeycomb Biotechnologies, a trailblazer in instrument-free cellular analysis. This collaboration aims to revolutionize the landscape of single-cell genomics through a high-throughput, flexible workflow that leverages the strengths of both companies.
The cornerstone of this innovative partnership is the integration of Factorial’s proprietary in-cell library preparation technology with Honeycomb’s well-regarded HIVE™ platform. Together, they seek to enable researchers to perform single-cell whole genome sequencing (WGS) with remarkable ease—processing capabilities are projected to reach up to a staggering 1 million cells per day without the need for specialized instruments, which is a significant advancement in the field.
This collaboration addresses a critical requirement within the realm of single-cell genomics: the need for both high throughput and high resolution. Many existing single-cell DNA sequencing methods come with trade-offs, where either throughput or genomic coverage is sacrificed. By marrying Factorial’s extraction-free library preparation with Honeycomb’s cell barcoding technologies, the new joint solution promises to keep genomic integrity intact while allowing for unprecedented scale in cell analysis.
John Wells, the founder and CEO of Factorial Biotechnologies, expressed enthusiasm about the union, highlighting the potential of combining their effective library preparation chemistries with Honeycomb’s innovative approach to cell partitioning. "What excites me most about this partnership is combining Factorial’s scalable library prep chemistries with an elegant and robust cell partitioning solution," he noted. His excitement reflects a shared vision of both companies to lower the barriers to scientific exploration with cutting-edge technology.
Jim Flanigon, CEO of Honeycomb Biotechnologies, echoed this sentiment, expressing eagerness to expand beyond single-cell RNA sequencing. He stated that combining their existing platform with Factorial’s technology could unlock new possibilities for single-cell genomics.
The HIVE platform, known for its handheld, user-friendly design, has previously facilitated gentle cell capture and processing without the need for complex machinery typical in traditional laboratory settings. Now, with the integration of Factorial’s library preparation methodologies, researchers are poised to capitalize on the benefits of this technology for in-depth genomic analysis and multi-omic profiling, which enables simultaneous study of DNA, RNA, and protein from individual cells.
Chris Love, co-founder of Honeycomb and a professor at MIT’s Koch Institute, highlighted the significant impact that instrument-free single-cell DNA sequencing will have on various research fields. He noted that this advancement could significantly expedite discoveries within somatic mosaicism, tumor evolution, and gene editing.
The partnership between Factorial and Honeycomb represents a strategic move to dismantle the technical barriers often encountered in genomic research, thus broadening access to single-cell resolution data. As researchers strive for more profound insights into complex biological systems, this collaboration sets the stage for transformative advancements in genomic research.
In conclusion, the merger of Factorial Biotechnologies’ innovative sequencing methods with Honeycomb Biotechnologies’ established HIVE platform enables a new era of high-throughput sequencing that is more accessible and efficient. As beta testing steps are underway, the scientific community is eager to witness the potential breakthroughs that will arise from this partnership, showcasing the limitless possibilities in the realms of genomics and molecular biology.
The cornerstone of this innovative partnership is the integration of Factorial’s proprietary in-cell library preparation technology with Honeycomb’s well-regarded HIVE™ platform. Together, they seek to enable researchers to perform single-cell whole genome sequencing (WGS) with remarkable ease—processing capabilities are projected to reach up to a staggering 1 million cells per day without the need for specialized instruments, which is a significant advancement in the field.
This collaboration addresses a critical requirement within the realm of single-cell genomics: the need for both high throughput and high resolution. Many existing single-cell DNA sequencing methods come with trade-offs, where either throughput or genomic coverage is sacrificed. By marrying Factorial’s extraction-free library preparation with Honeycomb’s cell barcoding technologies, the new joint solution promises to keep genomic integrity intact while allowing for unprecedented scale in cell analysis.
John Wells, the founder and CEO of Factorial Biotechnologies, expressed enthusiasm about the union, highlighting the potential of combining their effective library preparation chemistries with Honeycomb’s innovative approach to cell partitioning. "What excites me most about this partnership is combining Factorial’s scalable library prep chemistries with an elegant and robust cell partitioning solution," he noted. His excitement reflects a shared vision of both companies to lower the barriers to scientific exploration with cutting-edge technology.
Jim Flanigon, CEO of Honeycomb Biotechnologies, echoed this sentiment, expressing eagerness to expand beyond single-cell RNA sequencing. He stated that combining their existing platform with Factorial’s technology could unlock new possibilities for single-cell genomics.
The HIVE platform, known for its handheld, user-friendly design, has previously facilitated gentle cell capture and processing without the need for complex machinery typical in traditional laboratory settings. Now, with the integration of Factorial’s library preparation methodologies, researchers are poised to capitalize on the benefits of this technology for in-depth genomic analysis and multi-omic profiling, which enables simultaneous study of DNA, RNA, and protein from individual cells.
Chris Love, co-founder of Honeycomb and a professor at MIT’s Koch Institute, highlighted the significant impact that instrument-free single-cell DNA sequencing will have on various research fields. He noted that this advancement could significantly expedite discoveries within somatic mosaicism, tumor evolution, and gene editing.
The partnership between Factorial and Honeycomb represents a strategic move to dismantle the technical barriers often encountered in genomic research, thus broadening access to single-cell resolution data. As researchers strive for more profound insights into complex biological systems, this collaboration sets the stage for transformative advancements in genomic research.
In conclusion, the merger of Factorial Biotechnologies’ innovative sequencing methods with Honeycomb Biotechnologies’ established HIVE platform enables a new era of high-throughput sequencing that is more accessible and efficient. As beta testing steps are underway, the scientific community is eager to witness the potential breakthroughs that will arise from this partnership, showcasing the limitless possibilities in the realms of genomics and molecular biology.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.